Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 April 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Walena and Elize
Walena Marambakuyana and Elize Swartz.

Her love of numbers and analysing data – to such an extent that she, just for the fun of it, did university Mathematics in her spare time in Grade 10. This not only resulted in an A for Maths in matric, but also contributed to Walena Anesu Marambakuyana’s success during her postgraduate studies, as she was announced the best honours student in her year group in the Faculty of Natural and Agricultural Sciences. 

Solutions to Africa’s challenges

For this prestigious achievement, she was presented the Dean’s Medal, which she collected during the faculty’s graduation ceremony on 21 April 2022. “I can't begin to say how much this means to me. I think of the struggles that I've faced, and it just proves to me that anything is possible if you set your mind to it,” says Walena, who believes this achievement will also motivate her little sisters to aim higher in life. 

Walena, who completed her undergraduate studies in Actuarial and Financial Mathematics at the University of Pretoria, continued with her honour’s degree in Risk Analysis at the UFS.

“Thinking back, it was always clear that I would take this route. Throughout primary school and high school, the Math teachers particularly liked me. I think it was because they saw that I really enjoyed Mathematics. I also remember that at the tender age of seven, my dad's colleagues would call me a mathematician,” recounts Walena.

She, like her aunt and role model, Dr C Gandidzanwa, is working towards obtaining a PhD. Currently, Walena is enrolled for the master’s degree in Risk Analysis at the UFS. “In my view, a PhD would enable me to contribute to innovative ideas that will provide solutions to the various challenges we are facing in Africa and the world at large. I specifically would like to inspire younger generations coming after us to safeguard against risks by anticipating, assessing, and taking the necessary steps to mitigate against risks,” she says.

“I believe risk assessment and mitigation not only contribute to my day-to-day activities; it also affects bigger global challenges such as climate change. Through my studies, I have a clear picture of what can be done to mitigate these risks. However, the challenge is always to ensure that this filters to practical action,” says Walena.

This is where I belong

Receiving the Dean’s Medal for the best marks in the group of master’s students in the Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS), was another mathematician, Elize Swartz. “Receiving the Dean's Medal is a great honour for me. It reminds me that hard work pays off and it encourages me to continue with my studies.”

She completed her honours degree, majoring in Mathematics and Applied Mathematics, in 2019 and her master’s degree in Mathematics in 2021. For both, her mini thesis was in the field of graph theory.

Currently a lecturer in the UFS Department of Mathematics and Applied Mathematics, she is looking forward to starting with her PhD later this year. Elize, who already knew in primary school that she wanted to be a teacher, is hoping to one day be a full-time lecturer at the UFS. “My passion is to work with young people. I hope to make a difference in their lives by teaching, sharing my knowledge, and helping them in such a way that they experience the love of Jesus Christ,” she says. 

She continues: “I cherish the instances when my lecturers gave me advice, encouraged me, and recognised my hard work. I want to share and continue that positive experience with other people and students by teaching them to work hard and be responsible, while treating them with kindness, patience, and love.”

Her favourite part of studying was the moment when she did homework and assignment problems and everything just started to fall into place. “For me, Maths problems are almost like a little game or puzzle. I also enjoyed receiving my marks after each assignment, test, or exam, knowing that this was the result of all my hard work,” says Elize, who also enjoys campus life, especially after the lockdown, “walking on campus – feeling safe, at home, and the sense of knowing this is where I belong”.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept